Eli Lilly cuts Zepbound price by up to 20%: How much the weight loss drug costs now, and where to buy
Amid rising demand for weight-loss treatments, Eli Lilly said Monday it is lowering the price of its popular obesity drug Zepbound and moving to make the drug more accessible in line with the Trump administration’s goals.
On LillyDirect, Eli Lilly’s direct-to-consumer platform, the price of single-dose vials of weight-loss drug Zepbound has also been reduced as the company also races to compete with rival Novo Nordisk.
Price of Eli Lilly weight loss drug Zepbound after discount
In a statement on Monday, Eli Lilly said it would offer up to a 20% discount on its obesity drug Zepbound.
Lilly said in a statement that its lowest-dose vial will cost $299 a month for those paying cash, a discount of about $50. The next higher dose of 5 milligrams will cost $399 per month; this is approximately 20% less than the previous self-checkout price.
Higher doses will now be available for $449 per month under Lilly’s Zepbound Self-Pay Journey Program; this figure was previously $499; It’s a $50 discount.
Patients often start with lower doses before progressing to higher strengths for greater weight loss.
This is the second time the company has reduced Zepbound prices on LillyDirect.
Lilly USA president Ilya Yuffa said the Zepbound discounts underscore the company’s commitment to reducing America’s obesity problem.
“We will continue to work to provide more options, expand options for delivery devices, and create new pathways for access so more people can get the medications they need,” he said in a statement.
Zepbound is now more accessible
Zepbound has a list price of approximately $1,086 per month. This price point, along with patchy insurance coverage, makes the weight-loss drug inaccessible to many needy Americans suffering from obesity.
“Too many people needing obesity treatment still face cost and coverage barriers,” Yuffa said.
The announcement comes weeks after US President Donald Trump signed deals with Eli Lilly and Novo Nordisk to make GLP-1 drugs more affordable.
As part of this agreement, Lilly will cut the fee it charges for Zepbound multi-dose pens. The Trump agreement goes into effect starting in 2026 and applies to both Medicare and cash-pay customers.
Zepbound is approved to help adults with obesity or overweight lose excess weight. The drug is also approved to help adults with obesity and moderate to severe obstructive sleep apnea improve their condition.
